Clinical Trial: BGB-A317-A1217-301

Trial Status: Open
Disease Type: Lung
Trial ID BGB-A317-A1217-301
Sponsor ID BeiGene

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC

1 Location


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location